K. Jéhannin-ligier, E. Dantony, N. Bossard, F. Molinié, G. Defossez et al.,

P. Delafosse, L. Remontet, and Z. Uhry, Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique, vol.80, 2017.

F. Binder-foucard, N. Bossard, P. Delafosse, A. Belot, A. S. Woronoff et al.,

, Cancer incidence and mortality in France over the 1980-2012 period:solid tumors, Rev Epidemiol Sante Publique, vol.62, pp.95-108, 2014.

M. Colonna, E. Chatignoux, L. Remontet, N. Mitton, A. Belot et al.,

Z. Uhry, Estimations de l'incidence départementale des cancers en France métropolitaine 2008-2010. Étude à partir des données des registres des cancers du réseau Francim et des bases de données médico-administratives

D. K. Chopin and B. Gattegno, Superficial bladder tumors, Eur Urol, vol.42, issue.6, pp.533-574, 2002.

O. Bouchot and M. Zerbib, Treatments in invasive bladder cancer. Prog Urol, 2003.

R. L. Siegel, K. D. Miller, and A. Jemal, Cancer statistics, CA Cancer J Clin, vol.66, pp.7-30, 2016.

M. Rota, C. Bosetti, S. Boccia, P. Boffetta, L. Vecchia et al., Occupational exposures to polycyclic aromatic hydrocarbons and respiratory and urinary tract cancers: an updated systematic review and a meta-analysis to, Arch Toxicol, vol.88, pp.1479-90, 2014.

J. M. Underwood, T. B. Richards, S. J. Henley, B. Momin, K. Houston et al., Decreasing trend in tobacco-related cancer incidence, United States, J Community Health, vol.40, p.33, 2005.

M. Keimling, G. Behrens, D. Schmid, C. Jochem, and M. F. Leitzmann, The nassociation between physical activity and bladder cancer: systematic review and meta-analysis, Br J Cancer, vol.110, pp.1862-70, 2014.

M. Montella, D. Maso, M. Crispo, A. Grimaldi, M. Bosetti et al., Metabolic syndrome and the risk of urothelial carcinoma of the bladder: a case-control study, BMC Cancer, vol.15, p.720, 2015.

M. Rouprêt, Y. Neuzillet, A. Masson-lecomte, C. P. Compérat, E. Dubosq et al., CCAFU french national guidelines 2016-2018 on bladder cancer, Prog Urol, vol.27, issue.1, pp.67-91, 2016.

R. W. Dobbs, L. A. Hugar, L. M. Revenig, S. Al-qassab, J. A. Petros et al., Incidence and clinical characteristics of lower urinary tract symptoms as a presenting symptom for patients with newly diagnosed bladder cancer, Int Braz J Urol, vol.40, pp.198-203, 2014.

C. Pfister, M. Roupret, Y. Neuzillet, S. Larre, G. Pignot et al.,

, Recommandations en onco-urologie 2013 du CCAFU : Tumeurs de la vessie, Prog Urol, vol.23, pp.105-130, 2013.

S. Hafeez and R. Huddart, Advances in bladder cancer imaging, BMC Med, vol.11, p.104, 2013.

M. Burger, H. B. Grossman, M. Droller, J. Schmidbauer, G. Hermann et al., Photodynamic diagnosis of non-muscleinvasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data, Eur Urol, vol.64, pp.846-54, 2013.

R. J. Sylvester, W. Oosterlinck, S. Holmang, M. R. Sydes, A. Birtle et al.,

, Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa-pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?, Eur Urol, vol.69, pp.231-275, 2016.

A. Witjes, J. Lebret, T. Comperat, E. M. Cowan, N. C. et al., EAU Guidelines on Muscleinvasive and Metastatic Bladder Cancer, 2016.

R. T. Divrik, A. F. Sahin, U. Yildirim, M. Altok, and F. Zorlu, Impact of routine second transurethral resection on the long-term outcome of patients with newly diagnosed pT1 urothelial carcinoma with respect to recurrence, progression rate, and disease-specific survival: a prospective randomised clinical trial, Eur Urol, vol.58, issue.2, p.90, 2010.

M. Cumberbatch, B. Foerster, J. Catto, A. M. Kamat, W. Kassouf et al.,

, Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review, Eur Urol, 2018.

L. H. Sobin, M. K. Gospodarowicz, and C. Wittekind, TNM classification of malignant tumors, pp.262-267, 2009.

V. Molinié, Classification of bladder tumors in 2006, Prog Urol FMC, pp.16-23, 2006.

A. Witjes, J. Lebret, T. Comperat, E. M. Cowan, N. C. et al., Updated 2016 EAU Guidelines on Muscleinvasive and Metastatic Bladder Cancer, Eur Urol, vol.71, issue.3, pp.462-475, 2017.

M. Yin, M. Joshi, R. P. Meijer, M. Glantz, S. Holder et al., Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis, Oncologist, vol.21, pp.708-723, 2016.

, Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol

H. J. Lavery, K. D. Stensland, G. Niegisch, P. Albers, and M. J. Droller, Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate, J Urol, vol.191, issue.4, pp.898-906, 2014.

G. Sondpave, B. H. Goldman, V. O. Speights, S. P. Lerner, D. P. Wood et al., Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy, Cancer, vol.115, issue.18, pp.4104-4113, 2009.

V. K. Pokuri, J. R. Syed, Z. Yang, E. P. Field, S. Cyriac et al., Predictors of Complete Pathologic Response (pT0) to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma, Clin Genitourin Cancer, vol.14, issue.1, pp.59-65, 2016.

J. Lin, M. Whalen, D. Holder, G. Hruby, G. J. Decastro et al., Neoadjuvant chemotherapy in the treatment of muscle invasive bladder cancer with mixed histology, Can J Urol, vol.20, issue.2, pp.6690-6695, 2013.

J. J. Meeks, J. M. Taylor, K. Matsushita, H. W. Herr, S. M. Donat et al., Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer, BJU Int, vol.111, issue.8, pp.325-355, 2013.

H. B. Grossman, R. B. Natale, C. M. Tangen, V. O. Speights, . Vogelzangnj et al.,

, Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer, N Engl J Med, vol.349, issue.9, pp.859-66, 2003.

P. Malmstrom, E. Rintala, R. Wahlqvist, P. Hellstrom, . Hellstens et al.,

, Five-year follow-up of a prospective trial ofradical cystectomy and neoadjuvant chemotherapy: nordic cys-tectomy trial 1, J Urol, vol.155, issue.6, pp.1903-1909, 1996.

J. P. Stein, G. Lieskovsky, R. Cote, S. Groshen, F. A. Boyd et al., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol, vol.19, pp.666-675, 2001.

D. Dindo, N. Demartines, and P. A. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, vol.240, issue.2, pp.205-213, 2004.

B. Malavaud, C. Vaessen, M. Mouzin, P. Rischmann, J. Sarramon et al.,

, Complications for radical cystectomy. Impact of the American Society of Anesthesiologists score, Eur Urol, vol.39, pp.79-84, 2001.

S. Chang, S. J. Wells, N. Peterson, M. Kovach, B. Cookson et al., Estimated blood loss and transfusion requirements of radical cystectomy, J Urol, vol.166, pp.2151-2154, 2001.

Y. Cerantola, M. Valerio, B. Persson, P. Jichlinski, O. Ljungqvist et al.,

, Guidelines for perioperative care after radical cystectomy for bladder cancer: Enhanced Recovery After Surgery (ERAS®) society recommendations, Clin Nutr, vol.32, pp.879-87, 2013.

C. T. Lee, S. S. Chang, A. M. Kamat, G. Amiel, T. L. Beard et al., Alvimopan accelerates gastrointestinal recovery after radical cystectomy: a multicenter randomized placebo-controlled trial, Eur Urol, vol.66, pp.265-72, 2014.

K. H. Pang, R. Groves, S. Venugopal, A. P. Noon, and J. Catto, Prospective Implementation of Enhanced Recovery After Surgery Protocols to Radical Cystectomy, Eur Urol, issue.17, pp.30660-30667, 2017.

A. Baldini, F. Fehri, H. Cerantola, Y. Bayle, F. Ravier et al.,

M. Colombel and L. Badet, Do initial experience with an enhanced recovery program after surgery (ERAS) improve postoperative outcomes after cystectomy, Prog Urol, 2018.

, , vol.28, pp.351-358

M. Mcleod, L. Breen, D. L. Hamilton, and A. Philp, Live strong and prosper: the importance of skeletal muscle strength for healthy ageing, Biogerontology, 2016.

B. Raynard and S. Antoun, Physiopathologie de la cachexie et de la sarcopénie, Traité de nutrition clinique, à tous âges de la vie, pp.619-648, 2016.

C. , European consensus on definition an diagnosis, Age Ageing, vol.39, pp.412-435, 2010.

K. Fearon, F. Strasser, S. D. Anker, I. Bosaeus, E. Bruera et al., Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, issue.5, pp.489-95, 2011.

W. Shen, M. Punyanitya, Z. Wang, D. Gallagher, M. P. St-onge et al.,

S. Heshka, Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional image, J Appl Physiol, vol.97, issue.6, pp.2333-2341, 2004.

M. Mourtzakis, C. M. Prado, J. R. Lieffers, T. Reiman, L. J. Mccargar et al., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care, Appl Physiol Nutr Metab, 2008.

. Baracos, Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses, Int J Biochem Cell Biol, vol.45, issue.10, pp.2302-2310, 2013.

F. Pamoukdjian, T. Bouillet, V. Lévy, M. Soussan, L. Zelek et al., Prevalence and predictive value of pre-therapeutic sarcopenia in cancer patients: A systematic review

, Clin Nutr, vol.37, issue.4, pp.1101-1113, 2018.

. Bozzetti, Forcing the vicious circle: sarcopenia increases toxicity, decreases response to chemotherapy and worsens with chemotherapy, Ann Oncol, vol.28, issue.9, pp.2107-2118, 2017.

S. Antoun, V. E. Baracos, L. Birdsell, B. Escudier, and M. B. Sawyer, Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma, Ann Oncol, vol.21, issue.8, pp.1594-1602, 2010.

A. B. Smith, A. M. Deal, H. Yu, B. Boyd, J. Matthews et al.,

H. Muss and M. E. Nielsen, Sarcopenia as a predictor of complications and survival following radical cystectomy, J Urol, issue.6, pp.1714-1734, 2014.

S. P. Psutka, A. Carrasco, G. D. Schmit, M. R. Moynagh, S. A. Boorjian et al.,

P. Thapa, R. F. Tarrell, J. C. Cheville, and M. K. Tollefson, Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer, vol.120, pp.2910-2918, 2014.

Y. Hirasawa, J. Nakashima, D. Yunaiyama, T. Sugihara, T. Gondo et al., Sarcopenia as a Novel Preoperative Prognostic Predictor for Survival in Patients with Bladder Cancer Undergoing Radical Cystectomy, Ann Surg Oncol, vol.23, issue.5, pp.1048-1054, 2016.

H. Zargar, N. Almassi, E. Kovac, C. Ercole, E. Remer et al.,

P. Grivas, Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer, vol.3, pp.57-63, 2017.

M. Miyake, Y. Morizawa, S. Hori, N. Marugami, K. Shimada et al., Clinical impact of postoperative loss in psoas major muscle and nutrition index after radical cystectomy for patients with urothelial carcinoma of the bladder. BMC Cancer, vol.17, p.237, 2017.

R. Mayr, M. Gierth, F. Zeman, M. Reiffen, P. Seeger et al.,

, Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer, J Cachexia Sarcopenia Muscle, vol.9, issue.3, pp.505-513, 2018.

R. Mayr, H. M. Fritsche, F. Zeman, M. Reiffen, L. Siebertz et al., Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer, World J Urol, 2018.

S. Madersbacher, W. Hochreiter, F. Burkhard, G. N. Thalmann, H. Danuser et al., Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy, J Clin Oncol: Official Journal of the American Society of Clinical Oncology, vol.21, pp.690-696, 2003.

J. P. Stein, G. Lieskovsky, R. Cote, S. Groshen, A. C. Feng et al., Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients, J Clin Oncol: Official Journal of the American Society of Clinical Oncology, vol.19, pp.666-675, 2001.

A. Shabsigh, Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology, Eur Urol, vol.55, pp.164-74, 2009.

H. Isbarn, A population based assessment of perioperative mortality after cystectomy for bladder cancer, The Journal of urology, vol.182, pp.70-77, 2009.

F. Roghmann, Standardized assessment of complications in a contemporary series of European patients undergoing radical cystectomy, Int J Urol, vol.21, pp.143-152, 2014.

, Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration, Eur Urol, vol.48, pp.202-207, 2005.

A. Witjes, J. Lebret, T. Comperat, E. M. Cowan, N. C. et al., EAU Guidelines on Muscleinvasive and Metastatic Bladder Cancer, 2016.

C. M. Prado, J. R. Lieffers, L. J. Mccargar, T. Reiman, M. B. Sawyer et al.,

, Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study, Lancet Oncol, 2008.

K. Kudou, H. Saeki, Y. Nakashima, K. Edahiro, S. Korehisa et al., Prognostic Significance of Sarcopenia in Patients with Esophagogastric Junction Cancer or Upper Gastric Cancer, Ann Surg Oncol, vol.24, issue.7, pp.1804-1810, 2017.

M. S. Sabel, J. Lee, S. Cai, M. J. Englesbe, S. Holcombe et al., Sarcopenia as a prognostic factor among patients with stage III melanoma, Ann Surg Oncol, vol.18, pp.3579-3585, 2011.

H. Ishihara, T. Kondo, K. Omae, T. Takagi, J. Iizuka et al., Sarcopenia predicts survival outcomes among patients with urothelial carcinoma of the upper urinary tract undergoing radical nephroureterectomy: a retrospective multi-institution study, Int J Clin Oncol, vol.22, pp.136-144, 2016.

A. B. Smith, A. M. Deal, H. Yu, B. Boyd, J. Matthews et al., Sarcopenia as a predictor of complications and survival following radical cystectomy, J Urol, vol.191, pp.1714-1720, 2014.

S. P. Psutka, A. Carrasco, G. D. Schmit, M. R. Moynagh, S. A. Boorjian et al.,

, Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancerspecific and all-cause mortality, Cancer, vol.120, pp.2910-2918, 2014.

Y. Hirasawa, J. Nakashima, D. Yunaiyama, T. Sugihara, T. Gondo et al.,

, Sarcopenia as a novel preoperative prognostic predictor for survival in patients with bladder cancer undergoing radical cystectomy, Ann Surg Oncol, vol.23, pp.1048-1054, 2016.

F. Wan, Y. Zhu, C. Gu, X. Yao, Y. Shen et al., Lower skeletal muscle index and early complications in patients undergoing radical cystectomy for bladder cancer, World J Surg Oncol, vol.12, p.14, 2014.

H. Zargar, N. Almassi, E. Kovac, C. Ercole, E. Remer et al.,

P. Grivas, Change in Psoas Muscle Volume as a Predictor of Outcomes in Patients Treated with Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. Bladder Cancer, vol.3, pp.57-63, 2017.

K. Fearon, F. Strasser, S. D. Anker, I. Bosaeus, E. Bruera et al., Definition and classification of cancer cachexia: an international consensus, Lancet Oncol, vol.12, pp.489-495, 2011.

L. Martin, L. Birdsell, N. Macdonald, T. Reiman, M. T. Clandinin et al.,

, Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index, J Clin Oncol, vol.31, pp.1539-1547, 2013.

L. H. Sobin, M. K. Gospodarowicz, and C. Wittekind, TNM classification of malignant tumors, International Union Against Cancer, pp.262-267, 2009.

V. Molinié, Classification of bladder tumors in 2006, Prog Urol FMC, pp.16-23, 2006.

A. S. Levey, A. Md;-lesley, . Stevens, . Md, H. Ms;-christopher et al.,

(. Yaping and . Lucy,

A. F. Castro, I. Mph;-harold, I. Feldman, and M. D. ,

J. W. Kusek, P. Eggers, P. Van-lente, P. Greene, P. ;. et al., New Equation to Estimate Glomerular Filtration Rate for the CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration), Annals of Internal Medicine, vol.150, issue.9, pp.604-613, 2009.

D. Dindo, N. Demartines, and P. A. Clavien, Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey, Ann Surg, vol.240, issue.2, pp.205-213, 2004.

R. Mayr, H. M. Fritsche, F. Zeman, M. Reiffen, L. Siebertz et al., Sarcopenia predicts 90-day mortality and postoperative complications after radical cystectomy for bladder cancer, World J Urol, 2018.

R. Mayr, M. Gierth, F. Zeman, M. Reiffen, P. Seeger et al.,

, Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer, J Cachexia Sarcopenia Muscle, vol.9, issue.3, pp.505-513, 2018.

. Serment-d'hippocrate,

, de mes chers condisciples, devant l'effigie d'Hippocrate, Je promets et je jure d'être fidèle aux lois de l'Honneur et de la probité dans l'exercice de La Médecine

, Je donnerai mes soins gratuits à l'indigent et n'exigerai jamais un salaire au-dessus de mon travail

, Admis dans l'intérieur des maisons, mes yeux ne verront pas ce qui se passe, ma langue taira les secrets qui me seront confiés et mon état ne servira pas à corrompre les moeurs ni à favoriser le crime

, Je ne permettrai pas que des considérations de religion, de nation, de race, de parti ou de classe sociale viennent s'interposer entre mon Devoir et mon patient

, Je garderai le respect absolu de la vie humaine dès sa conception. Même sous la menace, je n'admettrai pas de faire usage de mes connaissances médicales contre les lois de l'Humanité

, Respectueux et reconnaissant envers les Maîtres, je rendrai à leurs enfants l'instruction que j'ai reçue de leurs pères

, Que les hommes m'accordent leur estime si je suis fidèle à mes promesses, Que je sois couvert d'opprobre et méprisé de mes confrères si j'y manque